Advances in Preventive Medicine / 2012 / Article / Tab 2

Research Article

Evaluation of a Pilot Medication-Assisted Therapy Program in Kazakhstan: Successes, Challenges, and Opportunities for Scaleup

Table 2

Variables reported by medication-assisted treatment sites in Kazakhstan to the Republican Applied Research Center for Medicosocial Problems of Drug Addiction (RARC) and Republican AIDS Center (RAC).

Variables reported to the RARCVariables reported to the RAC

(i) Patients’ personal data(i) Patients’ sociodemographic profile
(ii) Patients’ sociodemographic profile(ii) Patients’ biopsychosocial status
(iii) Patients’ biopsychosocial status(iii) Average daily dose of methadone per patient
(iv) Years of drug use(iv) Remaining amount of methadone
(v) Information about types of treatment currently and previously received(v) Number of new patients
(vi) Date of initiation of MAT(vi) Number of dropouts and reasons for dropout
(vii) Clinical diagnosis based on ICD-10(vii) Criminal charges
(viii) Daily dose of methadone prescribed(viii) Concurrent illnesses including HIV, hepatitis B (HBV), hepatitis C (HCV), and tuberculosis
(ix) Changes in prescribed dose of methadone and reason for the changes
(x) Number of new patients
(xi) Number of dropouts and reasons for dropout
(xii) Criminal charges
(xiii) Concurrent illnesses including HIV, hepatitis B, hepatitis C, and tuberculosis
(xiv) Laboratory test results
(xv) Results of psychological assessment with dates
 (a) Short form of Minnesota Multiphasic Personality Inventory (MMPI-Short)
 (b) Addiction Severity Index
 (c) Zung Self-Rating Depression Scale
 (d) WHO QOL-100 (Quality of Life)
(xvi) Description of side effects related to MAT with observation dates
(xvii) Description of changes in patients’ social well-being
(xvii) Outcomes of therapy
(xix) Reasons for exclusion from MAT (if applicable)